Comera Life Sciences (CMRAW) Stock Analysis

What Comera Life Sciences does

Comera Life Sciences Holdings, Inc. is an early-stage life sciences company dedicated to developing its own innovative therapeutics. These treatments leverage its unique SQore formulation platform, which is engineered to convert biologics typically administered intravenously (IV) into convenient subcutaneous (SQ) versions. The company's pipeline currently features two primary drug candidates: CLS-001, an improved biologic in preclinical development, targets Crohn's and Ulcerative Colitis; and CLS-002, also in preclinical stages, is an enhanced biologic aimed at various oncological indications. Established in 2014, Comera Life Sciences is based in Woburn, Massachusetts.

Key metrics

ETFs linked to CMRAW

Broad-market and Healthcare sector ETFs an investor holding Comera Life Sciences is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CMRAW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Comera Life Sciences?

Comera Life Sciences trades under the ticker CMRAW on NASDAQ.

Which exchange is CMRAW listed on?

CMRAW is listed on NASDAQ.

What sector does Comera Life Sciences operate in?

Comera Life Sciences is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CMRAW in a portfolio?

PortView shows CMRAW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.